Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03384043 |
Recruitment Status :
Completed
First Posted : December 27, 2017
Last Update Posted : July 8, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer Disease Cognitive Impairment, Mild Dementia, Mild | Behavioral: Smartphone Personal Assistant Behavioral: Implementation Intention | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 52 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Care Provider, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | Using Smartphone Personal Assistant Technology to Improve Prospective Memory in Alzheimer's Disease |
Actual Study Start Date : | January 8, 2018 |
Actual Primary Completion Date : | February 28, 2020 |
Actual Study Completion Date : | February 28, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Smartphone Personal Assistant
Participants will use the personal assistant feature of the smartphone ("Cortana") to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state "Cortana, I need to remember to..." for time--based tasks ("...take my medicine at 7pm") and event--based tasks ("pick-up milk at the grocery store).
|
Behavioral: Smartphone Personal Assistant
Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location. |
Active Comparator: Implementation Intention
The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a "When…then" format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks ("When it is 7pm, then I will remember to take my medicine"), and event--based tasks ("When I am at the grocery store, then I will remember to pick--up milk).
|
Behavioral: Implementation Intention
Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment. |
- Objective Prospective Memory Performance [ Time Frame: Measured for 4 weeks. ]Performance on the experimenter-assigned time-based and event-based prospective memory tasks (number of tasks completed).
- Quality of Life - Positive Affect and Well-Being [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]Participants will complete the Quality of Life in Neurological Disorders (Neuro-QOL) subscale titled "Positive Affect and Well-Being." This subscale has 9 items that are rated from Never to Always. The subscale total scores range from 9 (minimum) to 45 (maximum), with higher scores indicating better outcomes
- Quality of Life - Ability to Participate in Social Roles and Activities [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]Participants will complete the Quality of Life in Neurological Disorders (Neuro-QOL) subscale titled "Ability to Participate in Social Roles and Activities." This subscale has 8 items that are rated from Never to Always. The subscale total scores range from 8 (minimum) to 40 (maximum), with higher scores indicating better outcomes.
- Quality of Life - Satisfaction with Social Roles and Activities [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]Participants will complete the Quality of Life in Neurological Disorders (Neuro-QOL) subscale titled "Satisfaction with Social Roles and Activities." This subscale has 8 items that are rated from Not at All to Very Much. The subscale total scores range from 8 (minimum) to 40 (maximum), with higher scores indicating better outcomes.
- Quality of Life - Cognitive Function [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]Participants will complete the Quality of Life in Neurological Disorders (Neuro-QOL) subscale titled "Cognitive Function." This subscale has 8 items. The first four items are rated from Never to Very Often, and the last four items are rated from No Difficulty to Cannot Do. The subscale total scores range from 8 (minimum) to 40 (maximum), with higher scores indicating better outcomes.
- Subjective Memory Performance Questionnaire [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]The Prospective and Retrospective Memory Questionnaire uses a 5-point scale to assess the frequency of retrospective and prospective memory failures such as forgetting to take a pill.
- Perceived Memory Structured Interview [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]The experimenter will conduct a structured interview session at baseline to determine participants' most important, common, and challenging prospective memory tasks. At follow-up, participants will rate whether each memory issue described at baseline was much worse (1), worse (2), normal (3), better (4), or much better (5) than usual over the last month.
- Use of Technology/Strategy [ Time Frame: Measured for 4 weeks ]The number of times the personal assistant feature and voice-recorder system were used.
- Instrumental Activities of Daily Living [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]Scale on participants' ability to complete instrumental activities of daily living, such as housekeeping, financing, and medication activities.
- Smartphone Acceptability/Usability Scale [ Time Frame: Pre-Intervention and Post-Intervention (4 weeks) ]Scale to assess the acceptability and usability of the smartphone (Ben Zeev et al., 2014). The scale includes 26 items to which participants respond agree, neutral, or disagree, with agree indicating the favorable outcome on 21 items, and disagree indicating the favorable outcome on 5 items.
- Training Duration [ Time Frame: Pre-Intervention ]Number of minutes to complete smartphone training

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of MCI or dementia at a neurology and/or neuropsychology office visit in the BSWH Temple region, or neuropsychology office visit in the RR BSWH region within 12 months of the study contact (Specific ICD Codes outlined below).
- Interest in participating in research
- Able and willing to bring a legally authorized representative (spouse or medical power of attorney) to initial training session.
- Able to independently consent according to the results of a structured capacity to consent interview OR is interested after going through the consent process but does not pass capacity to consent inventory AND has a legally authorized representative available to provide proxy consent.
-
Presence of no more than mild dementia on the basis of telephone administered cognitive screening instrument (TICS-M) & Collateral/Informant ADL Measure
o Using the TICS-M and published normative data, all subjects must have scores that are around -1 to -2 standard deviations for demographically corrected norms (National Institute of Aging-Alzheimer's Association recommended criteria for the very mild to mild stages of Alzheimer's disease; Albert et al., 2011; McKhann et al., 2011).
- Etiology of the dementia or MCI can be varied or unknown at the time of the screening criteria.
Exclusion Criteria:
- Presence of severe cognitive impairment defined by a TICS-M score <-2 standard deviations from the mean.
-
Semi-structured telephone clinical interview and/or chart review suggest:
- Serious mental illness (schizophrenia, bipolar, or depression with suicidal ideation in the last 30 days) are present and significantly contributing to the current presentation
- Uncorrected hearing loss, visual loss, or motoric dysfunction would preclude using the smartphone.
- English language proficiency (whether due to English as a second language or the presence of aphasia) significantly interferes with completion of telephone screening procedures or would be clinically suspected to interfere with completion of the study process.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03384043
United States, Texas | |
Baylor Scott & White Medical Center | |
Temple, Texas, United States, 76508 |
Principal Investigator: | Michael Scullin, PhD | Baylor University |
Responsible Party: | Michael Scullin, Assistant Professor of Psychology and Neuroscience, Baylor University |
ClinicalTrials.gov Identifier: | NCT03384043 |
Other Study ID Numbers: |
017-327 1R21AG053161-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | December 27, 2017 Key Record Dates |
Last Update Posted: | July 8, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | De-identified data will be shared with any interested researcher who adheres to Health Insurance Portability and Accountability Act (HIPAA) requirements. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alzheimer Disease Cognitive Dysfunction Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Cognition Disorders |